MAPT and Alzheimer disease: These results provide further evidence that Ch4 degeneration occurs early, preceding hippocampal atrophy, a characteristic marker of neurodegeneration in AD, and highlight the link between Ch4 vulnerability and MTL tau pathology in the preclinical phase of the disease.